Literature DB >> 19741040

Effects of short-term and long-term pretreatment of Schisandra lignans on regulating hepatic and intestinal CYP3A in rats.

Li Lai1, Haiping Hao, Qiong Wang, Chaonao Zheng, Fang Zhou, Yitong Liu, Yuxin Wang, Guo Yu, An Kang, Ying Peng, Guangji Wang, Xijing Chen.   

Abstract

This study aimed to evaluate the effects of Schisandra lignan extract (SLE) with short- and long-term pretreatment on regulating rat hepatic and intestinal CYP3A for a comprehensive evaluation of metabolism-based herb-drug interactions. Inhibitory effects of SLE and its major components on rat CYP3A were confirmed in both hepatic and intestinal microsomal incubation systems. After a single dose of SLE pretreatment, higher C(max) and area under the concentration-time curves from zero to infinity (AUC(0-infinity)) values were observed for intragastric midazolam (MDZ), whereas those for the intravenous MDZ were little changed. The mechanism-based inhibition of SLE toward CYP3A was further confirmed in vivo, characterized with a recovery half-life of 38 h. In contrast, SLE long-term treatment enhanced both hepatic (2.5-fold) and intestinal (4.0-fold) CYP3A protein expression and promoted the in vivo clearance of MDZ. When MDZ was coadministered with SLE after a consecutive long-term treatment, the AUC(0-infinity) value of MDZ was still lower than that of the control group, suggesting a much stronger inducing than inhibiting effect of SLE toward CYP3A. Furthermore, the intragastric administration of SLE exhibited a more intensive regulating effect toward intestinal than hepatic CYP3A, which could be partially explained by the relatively high exposures of lignans in the intestine. In conclusion, this study provides a comprehensive map for showing the complicated effects of SLE and its components on regulating rat CYP3A. The important findings are that SLE possesses a much stronger inducing than inhibiting effect on CYP3A, as well as a more intensive regulating effect on intestinal than hepatic CYP3A.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19741040     DOI: 10.1124/dmd.109.027433

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  14 in total

1.  Schisandrol B protects against acetaminophen-induced hepatotoxicity by inhibition of CYP-mediated bioactivation and regulation of liver regeneration.

Authors:  Yiming Jiang; Xiaomei Fan; Ying Wang; Pan Chen; Hang Zeng; Huasen Tan; Frank J Gonzalez; Min Huang; Huichang Bi
Journal:  Toxicol Sci       Date:  2014-10-14       Impact factor: 4.849

2.  Population pharmacokinetic analysis of tacrolimus in Chinese cardiac transplant recipients.

Authors:  Yan Gong; Ming Yang; Yongfeng Sun; Jing Li; Yongning Lu; Xingang Li
Journal:  Eur J Hosp Pharm       Date:  2019-01-19

3.  Schisandrol B protects against cholestatic liver injury through pregnane X receptors.

Authors:  Hang Zeng; Yiming Jiang; Pan Chen; Xiaomei Fan; Dongshun Li; Aiming Liu; Xiaochao Ma; Wen Xie; Peiqing Liu; Frank J Gonzalez; Min Huang; Huichang Bi
Journal:  Br J Pharmacol       Date:  2017-03-16       Impact factor: 8.739

4.  Wuzhi Capsule Dosage Affects Tacrolimus Elimination in Adult Kidney Transplant Recipients, as Determined by a Population Pharmacokinetics Analysis.

Authors:  Lizhi Chen; Yunyun Yang; Xuebin Wang; Chenyu Wang; Weiwei Lin; Zheng Jiao; Zhuo Wang
Journal:  Pharmgenomics Pers Med       Date:  2021-09-03

5.  Wuzhi tablet (Schisandra Sphenanthera extract) protects against acetaminophen-induced hepatotoxicity by inhibition of CYP-mediated bioactivation and regulation of NRF2-ARE and p53/p21 pathways.

Authors:  Xiaomei Fan; Yiming Jiang; Ying Wang; Huasen Tan; Hang Zeng; Yongtao Wang; Pan Chen; Aijuan Qu; Frank J Gonzalez; Min Huang; Huichang Bi
Journal:  Drug Metab Dispos       Date:  2014-09-12       Impact factor: 3.922

6.  Pharmacokinetic and nephroprotective benefits of using Schisandra chinensis extracts in a cyclosporine A-based immune-suppressive regime.

Authors:  Qiao Lai; Jiabao Wei; Mohammed Mahmoodurrahman; Chenxue Zhang; Shijian Quan; Tongming Li; Yang Yu
Journal:  Drug Des Devel Ther       Date:  2015-08-28       Impact factor: 4.162

7.  Time- and NADPH-Dependent Inhibition on CYP3A by Gomisin A and the Pharmacokinetic Interactions between Gomisin A and Cyclophosphamide in Rats.

Authors:  Jianxiu Zhai; Feng Zhang; Shouhong Gao; Li Chen; Ge Feng; Jun Yin; Wansheng Chen
Journal:  Molecules       Date:  2017-08-08       Impact factor: 4.411

8.  Pharmacokinetic Evaluation of Clozapine in Concomitant Use of Radix Rehmanniae, Fructus Schisandrae, Radix Bupleuri, or Fructus Gardeniae in Rats.

Authors:  Dan-Dan Tian; Wei Wang; Hua-Ning Wang; Stephen Cho Wing Sze; Zhang-Jin Zhang
Journal:  Molecules       Date:  2016-05-27       Impact factor: 4.411

9.  Inhibitory effects of tanshinones towards the catalytic activity of UDP-glucuronosyltransferases (UGTs).

Authors:  Xu-Xin Zhang; Yun-Feng Cao; Li-Xuan Wang; Xiao-Lin Yuan; Zhong-Ze Fang
Journal:  Pharm Biol       Date:  2017-12       Impact factor: 3.503

10.  Combination Therapy of Wuweizi (Schisandrae Chinensis Fructus) and Dexamethasone Alleviated Dexamethasone-Induced Glucocorticoid Osteoporosis in Rats with Idiopathic Pulmonary Fibrosis.

Authors:  Zinan Qin; Siyu Li; Xiaojuan Zhang; Guoxiu Liu; Min Gu; Nan Zhang; Jiao Liu; Zhihong Ji; Keao Li; Yongpeng Han; Huaqiang Zhai
Journal:  Biomed Res Int       Date:  2020-03-19       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.